Member Info for Jace86

And CT scans usually lead to invasive and unnecessary surgery. There's a huge mental health impact there not to mention cost reduction and time reduction. Patients on incorrect pathways one of the biggest wastages in any healthcare setting.

Yes return was at 10p. 26mil mcap.

Promotions aren't free...

What would you rather...

Spin and talk or get on with business.

Yes, this end of the market relies on promotion for those not willing to research. By the time it's been 'promoted' it's been bought up and those buying later are effectively funding the selling of those that bought bottom.

When you say nothing to show, has the company made no progress or are there arrangements in place and now reagents formulated?

I'll keep saying, the price is irrelevant. With how much I've bought down here my break even is now significantly lower. But just a return to IPO sees a significant gain.

But I'll remind you, I'm not interested in IPO levels one bit.

Promotions aren't free...

What would you rather...

Spin and talk or get on with business.

Yes, this end of the market relies on promotion for those not willing to research. By the time it's been 'promoted' it's been bought up and those buying later are effectively funding the selling of those that bought bottom.

When you say nothing to show, has the company made no progress or are there arrangements in place and now reagents formulated?

I'll keep saying, the price is irrelevant. With how much I've bought down here my break even is now significantly lower. But just a return to IPO sees a significant gain.

But I'll remind you, I'm not interested in IPO levels one bit.

Share price is a buy op.

Company has been doing things right so far.

Company isn't in control of the price.

Even if you was only a buyer for a return to IPO level, the risk/return prospect here is looking well.

Personally here for much more than that.

Have seen the propaganda wheel in full swing today too to deflect from consistent failures at home...

The things spoken of have been known about for quite some time... Cars and aircraft for example...

Let's see if something does or doesn't happen...

It was one of the AGM resolutions.

No, it's right to ask a question and invoke discussion. Never apologise for that.

At this stage we don't exactly know why other supply options are being looked at but I don't think it will be for bad reasons.

Either way it was nice to get the update today.

Only thing missing for me was timescales (approx) for the next steps of the project. We are all being left to make assumptions.

But importantly everything is moving in the right directions apart from the share price. But the company and news cannot control that. Only way that changes is if someone decides to order a quarter of the company stock (that doesn't exist to buy).

It looks like fine tuning...

"Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation

mAb reporter protein developed and ready for test development

mAb supplier agreements extended to increase use case diversity"

After this I'd expect a delivery.

Interesting point on other suppliers. Maybe cost, supply level or even localisation being considered? But they've extended supply agreement with FJB.

Maybe there is a lab in the US that can synthesise there? Cutting out a lot of red tape... Similar with China? We don't know yet...

It reads though, to put my previous quotes at ease, that they are cracking on with lung tests before moving with the diversification.

Great news and yet we see these big round dumps.

How odd...

I'd like to hope the passing on of reagents is soon. I wonder if there's a paperwork trail to be now had in that they maybe need protecting/patenting in some way to prevent others from making their own and stealing the technology to make the test?

Again.

Oh well, means I pick up nearly 250k on the cheap.

I wonder if there actually is a sell order or if it's gamesmanship again?

Time will only tell.

I'd have hoped this would be a pipeline project instead so that we can crack on with lung cancer.

Depends how far off it is I guess but either way would still like to have an estimate on both.

This is the news that's needed.

They've been on a recruiting spree of late it's worth noting.

Obviously delayed. Would be nice to know why.

A couple of 0's and then some...

The potential really is enormous. If a finished product is as good or close to the lab test, then this goes ballistic with an eventual equity offer IMO.

Big investors aren't seeing a finished product.

They see the risk that we are taking the opportunity to buy into at a low price.

Think of any take over, it doesn't ever happen in what is the R+D/Exploration phase.

It happens with a finished product that has significant interest and marketing capability.

For a large company to buy, they may also have presets on mcap. Many won't buy sub 100mil others 250mil and so on.

This is where the retail investor has an advantage.

Ignore the price, look at the news. Do you think it's heading in the right direction so far? Is there anything else they could or should be doing in your view?

The price I say to ignore because it's not driven by the company. There's quite obvious other reasons for it. So down here I'm buying more as I have the opportunity.

Only real difference at this level between aim and main market is aim carries zero stamp.

If the company does as we hope it's far less complicated further on down the line.

Dvharrison - this is exactly my point recently.

If there are sells, there should be stock to purchase. Why isn't there?

Who's holding the stock therefore and for what purpose...

Some it seems make fortunes off manipulating prices downwards...

Try and buy those block sells...

That mcap potential or even offer for equity is why I keep on buying.

I'm not here for a few quid and kept holding my original holding from BOU whilst adding on the way down.

Short term the price hurts but the potential really is astronomical.

I wouldn't take less than a 10 figure valuation.

Sorry to hear that Alan.

I'd hope that in time cancer treatment will change, I've always thought of Chemo and Radio as being a bit brutal and taking a chance. Purposely mutating DNA so that what your body replicates and prevents cancers growing is always a risk.

I'd much prefer to see protein therapy. Many cancers come from protein expressions messing up. P53 for example. If it fails to control what new cells/DNA look like this is how disease starts. Not always cancer of course but failure in this expression is often associated with the growth of it.

For me, a two fold approach, firstly preventing the body from creating its own targeted expression and then injecting a synthetic equivalent would be much better. Maybe even later editing genes so that these expressions are then corrected to avoid a lifetime of therapy although I personally wouldn't complain if it was an only option.

This for me would start with bio markers. Detecting the bio markers would allow a pathway decision on which expression(s) could be at fault.